SCHEMBL70602

SCHEMBL70602

N#Cc1ccc(-c2ccccc2)cn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.63
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
EGLN2 Q96KS0 1/20 0.47
NPC1 O15118 2/20 0.45
NFKB1 P19838 2/20 0.45
RAB9A P51151 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CYP11B2 P19099 2/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DGAT1 O75907 1/20 0.43
CTSA P10619 1/20 0.43
ATM Q13315 1/20 0.42
ADORA1 P30542 2/20 0.42
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31588411 1.00 CHEK1 (0.63) CHEK1ALDH1A1NPSR1TDP1EGLN2
SCHEMBL12630708 0.91 CHEK1 (0.51) CHEK1EGLN2CYP11B2DGAT1CTSA
SCHEMBL17116597 0.85 DGAT1 (0.48) CHEK1ALDH1A1NPSR1TDP1EGLN2
SCHEMBL18462116 0.85 CHEK1 (0.49) CHEK1ALDH1A1NPSR1TDP1EGLN2
SCHEMBL17117049 0.84 EGLN2 (0.49) CHEK1ALDH1A1NPSR1TDP1EGLN2
SCHEMBL9024185 0.83 CYP11B2 (0.53) CHEK1EGLN2CYP11B2DGAT1GABRA1
SCHEMBL18461464 0.83 CHEK1 (0.48) CHEK1ALDH1A1NPSR1TDP1EGLN2
SCHEMBL30518548 0.82 CYP11B2 (0.62) CHEK1ALDH1A1EGLN2SMN1; SMN2CYP11B2
SCHEMBL18404929 0.82 CYP11B2 (0.62) CHEK1ALDH1A1EGLN2SMN1; SMN2CYP11B2
SCHEMBL7285319 0.82 MMP3 (0.52) CHEK1EGLN2NPC1RAB9ADGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120028308-A Small molecule Raman probe, bar code probe, encoding method and application thereof 北京大学 2025-05-23 CN claimed
EP-4652168-A1 5-AMINO-1H-PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2025-11-26 EP disclosed
US-20250340554-A1 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 BEONE MEDICINES I GMBH (CH) 2025-11-06 US disclosed
CN-111480245-B Light-emitting element, light-emitting device, electronic apparatus, and lighting device 株式会社半导体能源研究所 2025-06-24 CN disclosed
CN-120028308-A Small molecule Raman probe, bar code probe, encoding method and application thereof 北京大学 2025-05-23 CN disclosed
WO-2024153230-A1 5-AMINO-1H-PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE, LTD. (KY) 2024-07-25 WO disclosed
CN-111778720-A Moisture-proof leather garment and processing technology thereof 温州厚德服饰有限公司 2020-10-16 CN disclosed
CN-111480245-A Light-emitting element, light-emitting device, electronic device, and lighting device 株式会社半导体能源研究所 2020-07-31 CN disclosed
CN-108864041-A A kind of preparation method of medicine intermediate tetrazole compound 北京京大律业知识产权代理有限公司 2018-11-23 CN disclosed
CN-108620115-A A kind of ternary metal mesoporous catalyst and its preparation method and application 北京京大律业知识产权代理有限公司 2018-10-09 CN disclosed
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-03 US disclosed
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-03 US disclosed
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-03 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed
WO-2008157844-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-12-24 WO disclosed
WO-2008157844-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-12-24 WO disclosed
US-6150379-A BLOOD COAGULATION FACTOR XA INHIBITORS; TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE ACTIVITY; THROMBOLYTIC AND ISCHEMIC AGENTS; E.G., 2-(6-(5-AMIDINO-1H-BENZIMIDAZOL-2-YL)-PYRID-3-YLCARBONYLAMINO)-3 -HYDROXYBUTYRIC ACID AXYS PHARMACEUTICALS, INC. (US) 2000-11-21 US disclosed
WO-1999026941-A1 SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS AXYS PHARMACEUTICALS, INC. (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 CHEK1 48/4885ALDH1A1 4811/4885NPSR1 3790/4885
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 CHEK1 4635/4885ALDH1A1 969/4885NPSR1 3073/4885
US-20250340554-A1 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 PRMT5, PRMT1, PRMT3 CHEK1 438/4885ALDH1A1 4004/4885NPSR1 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.